To investigate the effects of calcitriol and tacalcitol on breast cancer progression, we assessed tumor growth, vascularization, and potential toxicity of treatment using caliper measurements, contrast-enhanced ultrasonography, CD31 immunohistochemistry, blood morphology, plasma biochemistry, and ELISA assay. Here, PECAM1 is linked to breast cancer.